Watermark
Go to Asia edition

Alizyme

  • 22 Apr 2005

Nomura is leading a £30.5m capital increase for Alizyme, which develops treatments for obesity and gastrointestinal complaints.

Shareholders will be offered 30.5m shares in the company, equal to about 21% of its share capital, on a four-for-19 basis at a subscription price of 100p, a ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial
Log in

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.

Bond Comments

All International Bonds

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Citi 208,286.52 735 8.70%
2 JPMorgan 180,312.22 801 7.53%
3 Bank of America Merrill Lynch 175,954.61 579 7.35%
4 Barclays 152,682.63 530 6.38%
5 HSBC 132,711.10 607 5.54%

Bookrunners of All Syndicated Loans EMEA

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 JPMorgan 28,912.55 42 8.17%
2 BNP Paribas 23,481.31 80 6.63%
3 Citi 19,694.20 52 5.56%
4 SG Corporate & Investment Banking 18,198.32 63 5.14%
5 Credit Agricole CIB 18,113.59 74 5.12%

Bookrunners of all EMEA ECM Issuance

Rank Lead Manager Amount $m No of issues Share %
View full table
For detailed analysis: Dealogic
  • Last updated
  • Today
1 Goldman Sachs 9,045.53 40 8.97%
2 JPMorgan 8,516.92 36 8.45%
3 Citi 7,537.45 40 7.48%
4 UBS 5,926.29 19 5.88%
5 Deutsche Bank 5,145.17 32 5.10%